Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH

Key Points

Potent and selective compound ALG-055009 targets thyroid hormone receptor beta, providing a specialized candidate for the treatment of liver MASH.
Clinical evidence demonstrates that thyroid hormone receptor beta agonists lower LDL cholesterol and triglyceride levels during dyslipidemia trials.
Preclinical profile assessments characterize the selective THR-β agonist ALG-055009—preclinical model evaluation warrants further confirmation.

We only have this paper's title and publication details.

Preclinical study reveals the selective THR-β agonist ALG-055009 in disease models, highlighting a potential targeted intervention for MASH.

No takes yet. Share an insight, caveat, or question.

Vandyck et al. (2024) studied this question.

View at Publisher

Ask AI

Bookmark

Share